We will ultimately continue to open through commercial and non-commercial channels, looking at innovative ways to improve access and affordability. We will continue to track the number of countries we are able to distribute the totality of our portfolio to, as well as the number of direct import requests and direct institution requests.

This is certainly important for patients, but also great for business to ensure that we are able to address undeserved patients around the world. This is only one component of our overall international growth strategy, which is structured around three pillars.

Three pillars:

Growth in LMICs: This stage involves looking at low- and middle-income countries, as well as tapping into this next wave of geographies where markets are growing. We are currently seeing significant growth for market in Turkey, Hungary, and some Latin American markets.
China and Japan moonshot initiative: These markets are viewed as really ripe for innovation and significant investments are being made to drive greater access to patients in these regions.
Expanding our portfolio: BMS has a number of markets around the world where we don’t have a presence today, so we are expanding the number of markets we’re in and making sure to bring all (or most) of our products to maximize business opportunities.

Bristol Myers Squibb ASPIREs For Access In LMICs

In Vivo spoke with Adam Lenkowsky, executive vice-president, and chief commercialization officer at Bristol Myers Squibb

More from Global Vision

More from C-Suite Speaks